Brief: AC Immune Receives FDA Fast Track Designation For Anti-Amyloid-Beta Active Immunotherapy, ACI-24.060 To Treat Alzheimer’S Disease

AC Immune SA

27/06/2023 13:27

June 27 (Reuters) - AC Immune SA  ACIU.O :
    * AC IMMUNE RECEIVES FDA FAST TRACK DESIGNATION FOR
ANTI-AMYLOID-BETA ACTIVE IMMUNOTHERAPY, ACI-24.060, TO TREAT
ALZHEIMER’S DISEASE
    * AC IMMUNE SA-INTERIM SAFETY AND IMMUNOGENICITY DATA IN
ALZHEIMER'S DISEASE (AD) AND DS COHORTS EXPECTED IN H2 2023
    * AC IMMUNE SA-INITIAL PET DATA ON AMYLOID PLAQUE REDUCTION
IN AD
EXPECTED H1 2024
    * AC IMMUNE SA - DOSED FIRST INDIVIDUAL WITH DOWN SYNDROME
(DS) IN
DS COHORT OF ABATE
    * AC IMMUNE SA - INTERIM SAFETY AND IMMUNOGENICITY DATA IN
ALZHEIMER'S DISEASE (AD) AND DS COHORTS EXPECTED IN H2 2023

Source text for Eikon:  ID:nGNX17jmwM 
Further company coverage:  ACIU.O 

 ((reuters.briefs@thomsonreuters.com;))